New trade agreement between Mexico, the US and Canada

Home/Policies & Legislation | Posted 27/08/2021 post-comment0 Post your comment

The new trade agreement between Mexico, the US and Canada, now called the T-MEC entered into force on 1 July 2020. 

62 MD001919

When Mexico joined T-MEC with the US and Canada, it signed a chapter on medicines and health supplies in the agreement. Mexico agreed to unify criteria and conducts among the three bodies that regulate the authorization, use and marketing of drugs.

The purpose was to ensure the availability of patented and generic drugs as well as homogenize the market. With this, the population could be better served from a more unified criterion.

To avoid that the Mexican pharmaceutical industry from being dominated by Asian and Indian regional investors, it will not be surprising that the harmonization of policies and procedures of the Federal Commission for the Protection against Sanitary Risks (Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS), the US Food and Drug Administration (FDA) and the Canadian Agency for Drugs and Technologies in Health (CADTH) is accelerated within the framework of T-MEC.

The entry into force of the T-MEC trade agreement implied challenges and opportunities that must be addressed in a collaborative way among the multiplicity of participants in this regional market, in order to exploit the potential of the agreement as an instrument of regional economic recovery, and in the knowledge that its first review awaits us in 2026.

Related articles
A new decree modifies several aspects of the regulatory approval system for biosimilars in Mexico

Demand for similar biotherapeutic products in Latin America

A broader and stronger generic drug market is promoted in Mexico


The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: Solicitudes de biosimilares bajo evaluación de la EMA - julio de 2021

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.


Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Solicitudes de biosimilares bajo evaluación de la EMA - julio de 2021

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
PDUFA VI: FDA could promote generics competition
47 MD001813
Home/Policies & Legislation Posted 29/07/2022
House bill passes FDA funding fees but conflicts with Senate bill
User Fee V13H23
Home/Policies & Legislation Posted 15/07/2022
US Senate clarifies status of interchangeable biosimilar exclusivity
Interchangeability V18K30
Home/Policies & Legislation Posted 27/05/2022
Nomenclature of biologicals and biosimilars in Peru
02 AA010638
Home/Policies & Legislation Posted 20/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010